| Name | Title | Contact Details |
|---|
Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity`s greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio`s technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.
Beacon Biotechnology is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. We are dedicated to finding solutions for unmet medical need, such as drug resistance and tumor recurrence, in targeted therapy by degradation of disease-causing proteins with AbReptorTM platform. Novel degrader drugs have been exciting scientific field, due to its distinct mechanism of action (removal of disease-causing protein). AbReptorTM was developed for targeted degradation on membrane bound and extracellular proteins causing diseases. Receptor tyrosine kinase (RTK) and non-RTK inhibitors have made huge progress in the past few years, but their application is limited due to specificity, drug resistance, and on-target toxicity. Our platform`s RTK degraders promise to redefine their distinctive mutation-agnostic properties, differing from existing RTK therapeutics field. With the pre-clinical animal study, our lead molecule demonstrated on-target degradation, mutation agnostic anti-tumor effect, and potent anti-tumor effect in RTK inhibitor resistant tumor. Surprisingly, no signs of toxicity were found in rodent and cynomolgus monkey. Furthermore, it would unluck full potential to solve limitation of RTK and non-RTK therapeutics. Immune checkpoint inhibitors (ICIs) field made an initial breakthrough with poor response rate, high toxicity profiles, and exhausted poor clinical outcome. Our platform has full potential to solve the current problem of immune checkpoint inhibitors (ICIs), PD-(L)1 inhibitors. Our PD-(L)1 degrader is the first ever in-class to demonstrate enhanced anti-tumor immunity in pre-clinical animal studies. Pinetree Therapeutics` lead molecule is in pre-clinical IND stage, and we are committed to expanding our platforms to other target proteins, such as RTKs, non-RTKs, and ICIs. We believe our platform has the potential to transform the field of medicine and revolutionize the treatment of cancer and other diseases.
West Virginia Biometrics Initiative is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GRAIL`s mission is to detect cancer early, when it can be cured.